Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

June 2017 - FRMC

Department

Conference Insider
07/06/2017
Gary Owens, MD, a managed health care consultant and a First Report Managed Care Editorial Advisory Board member, presented “Improving Patient Outcomes with Novel Treatments and Strategies in the Management of Relapsing Multiple Sclerosis,”...
Gary Owens, MD, a managed health care consultant and a First Report Managed Care Editorial Advisory Board member, presented “Improving Patient Outcomes with Novel Treatments and Strategies in the Management of Relapsing Multiple Sclerosis,”...
Gary Owens, MD, a managed health...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
Steven R Feldman, MD, PhD, professor of dermatology at the Psoriasis Treatment Center at Wake Forest University School of Medicine, discussed how to improve treatment adherence and outcomes in patients with psoriasis at the NAMCP 2017 Spring...
Steven R Feldman, MD, PhD, professor of dermatology at the Psoriasis Treatment Center at Wake Forest University School of Medicine, discussed how to improve treatment adherence and outcomes in patients with psoriasis at the NAMCP 2017 Spring...
Steven R Feldman, MD, PhD,...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
A quality improvement initiative using fecal immunochemical testing (FIT) and colonoscopy was able to improve colorectal cancer (CRC) screening uptake in a managed care setting, according to a poster presented at Digestive Disease Week 2017.
A quality improvement initiative using fecal immunochemical testing (FIT) and colonoscopy was able to improve colorectal cancer (CRC) screening uptake in a managed care setting, according to a poster presented at Digestive Disease Week 2017.
A quality improvement initiative...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
Research presented at Digestive Disease Week 2017 found that switching from Remicade (infliximab; Janssen) to Inflectra (infliximab-dyyb; Pfizer) did not cause inflammatory bowel disease (IBD) symptoms to evolve among a patient cohort in...
Research presented at Digestive Disease Week 2017 found that switching from Remicade (infliximab; Janssen) to Inflectra (infliximab-dyyb; Pfizer) did not cause inflammatory bowel disease (IBD) symptoms to evolve among a patient cohort in...
Research presented at Digestive...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
A recent presentation at Digestive Disease Week 2017 showed that integrated models of care improve management and outcomes of inflammatory bowel diseases like Crohn disease and ulcerative colitis.
A recent presentation at Digestive Disease Week 2017 showed that integrated models of care improve management and outcomes of inflammatory bowel diseases like Crohn disease and ulcerative colitis.
A recent presentation at...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
Recent research from two phase 3 clinical trials, presented at Digestive Disease Week 2017, showed that Trulance (plecanatide; Synergy) is safe and effective at reducing symptom severity in patients with irritable bowel syndrome (IBS) with...
Recent research from two phase 3 clinical trials, presented at Digestive Disease Week 2017, showed that Trulance (plecanatide; Synergy) is safe and effective at reducing symptom severity in patients with irritable bowel syndrome (IBS) with...
Recent research from two phase 3...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
A study presented at Digestive Disease Week 2017 found that nonsurgical endoscopic sleeve gastroplasty may be an effective option for treating obesity in patients who are not candidates for surgery. 
A study presented at Digestive Disease Week 2017 found that nonsurgical endoscopic sleeve gastroplasty may be an effective option for treating obesity in patients who are not candidates for surgery. 
A study presented at Digestive...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
A majority of practitioners involved in clinical pathway development at three major oncology vendors received nonresearch general payments in 2015, according to research presented at the 2017 ASCO Annual Meeting.
A majority of practitioners involved in clinical pathway development at three major oncology vendors received nonresearch general payments in 2015, according to research presented at the 2017 ASCO Annual Meeting.
A majority of practitioners...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
A recent poster presentation at the 2017 ASCO Annual Meeting found that the clinical value of new oncology drugs is not in line with high price increases over time. 
A recent poster presentation at the 2017 ASCO Annual Meeting found that the clinical value of new oncology drugs is not in line with high price increases over time. 
A recent poster presentation at...
07/06/2017
First Report Managed Care
Conference Insider
07/06/2017
Recent research presented at the 2017 ASCO Annual Meeting found that after implementation of the ACA, there was a slight increase in the percentage of cancers diagnosed at an earlier, more treatable stage.
Recent research presented at the 2017 ASCO Annual Meeting found that after implementation of the ACA, there was a slight increase in the percentage of cancers diagnosed at an earlier, more treatable stage.
Recent research presented at the...
07/06/2017
First Report Managed Care

Advertisement

Advertisement

Advertisement